A troubled Chandler-based pharmaceutical firm that has been at the center of ongoing lawsuits and other action related to the national opioid epidemic has filed for bankruptcy protection.
In a regulatory filing Monday, Insys Therapeutics said it has sought Chapter 11 protection to facilitate a sale of most of its assets and address its legacy obligations such as a recent multimillion-dollar settlement with the federal government.
The company this month admitted to bribing doctors to write additional prescriptions for Subsys, a highly addictive fentanyl-based spray originally approved for cancer patients.
As part of that admission, the company agreed to pay $225 million to the federal government to settle civil and criminal cases.
